Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease
Syndax Pharmaceuticals and Incyte have announced positive topline data from the AGAVE-201 trial of axatilimab, an anti-CSF-1R antibody, in patients with chronic graft-versus-host disease (GVHD) who have undergone two or more prior lines of therapy
Source: Syndax Press Release
Feature
Text
FDA Approves New Treatment for Pneumonia Caused by Certain Difficult-to-Treat Bacteria
The U.S. Food and Drug Administration (FDA) has approved Xacduro (sulbactam for injection; durlobactam for injection) as a new treatment for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of the Acinetobacter baumannii-calcoaceticus complex in patients aged 18 years and older
Source: FDA Press Release
Text
Smartphone camera app to measure oxygenation levels
Researchers at the University of Washington have developed a smartphone system that can measure blood oxygen levels.
Source: Medgadet, Digital Medicine
Text
Novel Drugs & Emergent Therapeutics 2023 Archive
Text
